The Fungal Cyp51 Inhibitor VT-1129 Is Efficacious in an Experimental Model of Cryptococcal Meningitis

Documenti analoghi

• In Vivo Efficacy of VT-1129 against Experimental Cryptococcal Meningitis with the Use of a Loading Dose-Maintenance Dose Administration Strategy
  di: Wiederhold, Nathan P., et al.
  Pubblicazione: (2018)
• The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii
  di: Lockhart, Shawn R., et al.
  Pubblicazione: (2016)
• The Fungal Cyp51-Specific Inhibitor VT-1598 Demonstrates In Vitro and In Vivo Activity against Candida auris
  di: Wiederhold, Nathan P., et al.
  Pubblicazione: (2019)
• The Investigational Drug VT-1129 Is a Highly Potent Inhibitor of Cryptococcus Species CYP51 but Only Weakly Inhibits the Human Enzyme
  di: Warrilow, Andrew G. S., et al.
  Pubblicazione: (2016)
• Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong In Vitro Activity against Candida glabrata and C. krusei Isolates Clinically Resistant to Azole and Echinocandin Antifungal Compounds
  di: Schell, W. A., et al.
  Pubblicazione: (2017)